Detalhe da pesquisa
1.
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
N Engl J Med
; 381(18): 1718-1727, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31566307
2.
Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial.
Eur Respir J
; 59(3)2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34475231
3.
Effects of nintedanib by inclusion criteria for progression of interstitial lung disease.
Eur Respir J
; 59(2)2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34210788
4.
Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases.
Respirology
; 27(4): 294-300, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35224814
5.
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Respir Res
; 22(1): 84, 2021 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33726766
6.
The natural history of progressive fibrosing interstitial lung diseases.
Eur Respir J
; 55(6)2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32217654
7.
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone.
Eur Respir J
; 53(1)2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30442716
8.
Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Eur Respir J
; 54(3)2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31285305
9.
Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials.
Respir Res
; 19(1): 167, 2018 Sep 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30176872
10.
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria.
Am J Respir Crit Care Med
; 195(1): 78-85, 2017 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27331880
11.
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
N Engl J Med
; 370(22): 2071-82, 2014 May 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-24836310
12.
Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis.
Eur Respir J
; 49(5)2017 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-28526798
13.
Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.
Respirology
; 21(8): 1425-1430, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27399197
14.
Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.
BMC Pulm Med
; 16(1): 65, 2016 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27130202
15.
Reply to comment on "The natural history of progressive fibrosing interstitial lung diseases".
Eur Respir J
; 56(6)2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33334779
16.
Computed Tomographic Biomarkers in Idiopathic Pulmonary Fibrosis. The Future of Quantitative Analysis.
Am J Respir Crit Care Med
; 199(1): 12-21, 2019 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29986154
17.
Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials.
Eur Respir J
; 53(4)2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30655282
18.
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD Trial.
Arthritis Rheumatol
; 74(6): 1039-1047, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35199968
19.
Reply: Weight-Loss Effect on FVC in Nintedanib Idiopathic Pulmonary Fibrosis Trials?
Am J Respir Crit Care Med
; 192(8): 1020-1, 2015 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26469847
20.
Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey.
Adv Ther
; 38(2): 854-867, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33315170